Research paper
Repurposing drugs for treating the neurobehavioral manifestations of PTEN hamartoma tumor syndrome
iScience 2026 drug-repurposing study for PTEN-related disorders. Identifies approved compounds with mechanism-relevant activity that could be considered for off-label or trial-based use in PTEN hamartoma syndromes.
Fieblinger T, et al.
Markdown path
content/research/papers/2026-fieblinger-pten-drug-repurposing-iscience.mdFindings
iScience 2026 drug-repurposing study for PTEN-related disorders. Identifies approved compounds with mechanism-relevant activity that could be considered for off-label or trial-based use in PTEN hamartoma syndromes.
Why it may matter for Levi
If Levi is confirmed to have a PTEN variant (germline or mosaic), this paper expands the therapeutic options beyond rapalogs into potentially-accessible repurposed drugs. Strengthens the general argument that a confirmed PTEN diagnosis opens meaningful therapeutic doors. Not actionable without a confirmed diagnosis.
Fieblinger et al. (2026) — Drug repurposing for PTEN neurobehavioral phenotypes
Source
- iScience 29(4):115428, 2026.
Why in corpus
Groundbreaking 2026 drug-repurposing study for PHTS neurobehavioral manifestations (autism, intellectual disability) — areas where standard mTORC1-only inhibitors (rapamycin, everolimus) may be insufficient.
Key findings
- Screened 60+ compounds targeting the PI3K/AKT/mTOR pathway.
- Combined cell-line models, primary neurons with PTEN dysfunction, multielectrode array (MEA) recordings, and in vivo pharmacokinetic/pharmacodynamic studies.
- Identified 6 promising compounds.
- Dual PI3K/mTOR inhibitors achieved effects comparable to or surpassing standard mTOR inhibitors — suggests targeting multiple nodes may be necessary for the neurobehavioral axis.
Levi-relevant takeaways
- Extends the implications of the Lasser 2024 PTEN/mTORC1/mTORC2 finding already in the corpus. If a PTEN or PI3K-AKT-mTOR variant were ever identified in Levi, dual PI3K/mTOR inhibitors may outperform single-node rapalogs for the neurobehavioral (autism / cognitive) domain.
- Relevant to precision-therapy decision-making: epilepsy response alone would favor rapalogs (Ding 2026 meta); cognitive/behavioral response may require dual PI3K/mTOR.
- Complicates the "one drug for all axes" expectation — Levi's epilepsy, ASD features, and overgrowth may not all respond to the same mTOR-axis intervention.
- Still contingent on identifying a targetable variant; does not support empiric use.